Atlas FDA

Monovisc

FDA premarket approval P090031/S009 · decided 2020-01-09

Approval details

PMA number
P090031
Supplement
S009
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
Monovisc
Generic name
Acid, hyaluronic, intraarticular
Applicant
Anika Therapeutics, Inc.
Date received
2019-07-19
Decision date
2020-01-09
Days to decision
174 days
Decision code
APPR
Product code
MOZ
Advisory committee
Orthopedic
Expedited review
No
Location
Beford, MA
Statement
Approval for inclusion of new clinical evidence in the labeling (Information for Prescribers) for Monovisc.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Integrity™ Implant (K250997)Anika Therapeutics, Inc.2025-06-17
Tactoset® Injectable Bone Substitute (K231968)Anika Therapeutics, Inc.2023-12-20
Integrity Implant (K223538)Anika Therapeutics, Inc.2023-08-17
Integrity™ Bone Staple Fixation System (K223860)Anika Therapeutics, Inc.2023-05-22
Anika Tissue Tack Fixation System (K222487)Anika Therapeutics, Inc.2023-05-08
Tactoset (K223915)Anika Therapeutics, Inc.2023-03-29
Tactoset Injectable Bone Substitute (K212083)Anika Therapeutics, Inc.2021-08-31
SCS 17-01 (K190956)Anika Therapeutics, Inc.2020-01-30